跳至主要内容
MedPath Trial Home
临床试验
产品
机构
资讯
AI 研究
价格
Search
EN
登录
我们重视您的隐私
我们使用 Cookie 分析网站流量并改善您的体验。请参阅我们的
隐私政策
。
拒绝
接受
TIVICAY - Health Canada Drug Approval Details
Approvals
/
Health Canada
/
TIVICAY
Authorized
STANDARD
TIVICAY
viiv healthcare ulc
🇨🇦 Health Canada
Approval Date
Jul 4, 2025
Approval ID
398e0f39fb7cf6bc
Company
viiv healthcare ulc
Type
Standard
Approval Details
Approval Id
398e0f39fb7cf6bc
Drug Approval Canada Name
TIVICAY
Product Name
TIVICAY
Status
Marketed
Status Date
2022-01-31
Original Market Date
2022-01-31
Din
02511517
Drug Class
Human
Dosage Form
Tablet For Suspension
Route Of Administration
Oral
Schedule
Prescription
Ahfs
08:18.08.12
Atc Original
J05AJ03 DOLUTEGRAVIR
Atc Name
j 05 aj 03
Aig Number
0154870004
Company Name
viiv healthcare ulc
Company Address
1400, 75 Rue Queen, Montreal, Quebec, Canada, H3C 2N6
Active Ingredients
DOLUTEGRAVIR (DOLUTEGRAVIR SODIUM)
5 MG
Authorized
Quick Info
Agency
Health Canada
Country
🇨🇦
Approval Date
Jul 4, 2025
Approval ID
398e0f39fb7cf6bc
Type
Standard
Back to Health Canada Approvals